Abstract |
Prosthetic valve endocarditis (PVE) caused by Pseudomonas aeruginosa is a rare but life-threatening complication. Early surgical intervention, as well as appropriate antimicrobial therapy, is usually necessary. Recently, problems have arisen regarding infection with P. aeruginosa, which produces metallo- beta-lactamase (MBL) and is resistant to virtually all beta-lactams. This organism has rapidly spread through many countries. Here, we report the first case of successful redo aortic valve replacement using a Prima Plus stentless valve (Edwards Lifesciences, Irvine, CA, USA) followed by a 6-week course of ciprofloxacin and gentamicin for early PVE caused by MBL-producing P. aeruginosa.
|
Authors | Yasuyuki Kato, Hirokazu Ohashi, Yasushi Tsutsumi, Tadahiro Murakami, Yosuke Takahashi |
Journal | Journal of cardiac surgery
(J Card Surg)
2009 May-Jun
Vol. 24
Issue 3
Pg. 347-9
ISSN: 1540-8191 [Electronic] United States |
PMID | 19438796
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Gentamicins
- Ciprofloxacin
- metallo-beta-lactamase (VIM-13), Pseudomonas aeruginosa
- beta-Lactamases
|
Topics |
- Aged
- Anti-Bacterial Agents
(therapeutic use)
- Aortic Valve Stenosis
(surgery)
- Ciprofloxacin
(therapeutic use)
- Drug Therapy, Combination
- Echocardiography
- Endocarditis, Bacterial
(diagnosis, drug therapy, microbiology)
- Follow-Up Studies
- Gentamicins
(therapeutic use)
- Heart Valve Prosthesis
(adverse effects, microbiology)
- Humans
- Male
- Prosthesis-Related Infections
(diagnosis, drug therapy, microbiology)
- Pseudomonas Infections
(diagnosis, drug therapy, microbiology)
- Pseudomonas aeruginosa
(enzymology, isolation & purification)
- beta-Lactamases
(biosynthesis)
|